Giles Brown

Giles Brown is an accomplished pharmaceutical executive with extensive experience in medicinal chemistry and strategic leadership within biotechnology companies. Currently serving as SVP of Chemistry at Amphista Therapeutics Limited since June 2023, Giles is part of the executive leadership team guiding the organization's transition to a portfolio company and representing it in collaborations with BMS and Merck KGaA. Previously, as SVP of Medicinal Chemistry at Dunad Therapeutics, Giles played a pivotal role in expanding venture capital investments and representing the discovery department. Experience at OMass Therapeutics as VP, Head of Medicinal Chemistry, included significant financing activities, while earlier roles at Sosei Heptares involved leading teams on various projects, including the successful identification of drug candidates. Educational qualifications include an MBA from Henley Business School, a PhD in Organic Chemistry from the University of Bristol, and a post-doctoral research associate position at the University of Pennsylvania.